Abacus Health Products Announces New Retail Purchase Order for CBDMEDIC™ Products
July 17 2019 - 8:13AM
InvestorsHub Cannabis NewsWire
Abacus Health Products Announces
New
Retail
Purchase
Order for
CBDMEDIC™ Products
Woonsocket,
RI -- July 17, 2019 -- InvestorsHub NewsWire
-- Abacus Health Products, Inc.
(CSE: ABCS) (OTCQX: ABAHF) ("Abacus" or the
"Company")
today announced a new retail purchase order
by
Valu
Merchandisers
Company
for
its
line of
CBDMEDIC™ products.
Valu
Merchandisers
– a cooperative
food distributor serving over 3,800
independently-owned
supermarkets in 30 U.S. states – confirmed an order with Abacus
that will see 11
SKUs from the CBDMEDIC™ product line placed in 350
retail stores across six
states,
with expansion to more than 1,000 locations over the next six
months. This new purchase
order increases Abacus' total retailer
store
count to
approximately
2,550 locations in
15
states
throughout the
U.S. The
Company remains on track to reach 4,000 retail locations by the
end of Q3 2019, as per the guidance previously
provided by
management.
"Valu Merchandisers is a trusted
name in the health and wellness segment and we are delighted that they
have chosen to introduce CBDMEDIC™ to their
network," said Perry Antelman, CEO of
Abacus. "This purchase order
further illustrates how we continue
to execute
on our retail growth strategy and add retail chains
with significant
presence
across
the United
States."
# # #
About
Abacus Health Products, Inc.
Abacus is a
company engaged in the development and commercialization of
over-the-counter (OTC) registered topical medications with active
pharmaceutical ingredients and which contain organic and natural
ingredients, including a cannabinoid-rich hemp extract containing
CBD from Cannabis sativa L plant. Abacus' products are aimed at the
rapidly growing markets for topical pain relief and therapeutic
skincare and are based on proprietary patent-pending technologies
developed by Abacus. Abacus' formulations combine advanced science
with organic and natural ingredients to provide safe relief. Abacus
currently offers two lines of products: (i) CBD CLINIC™, marketed to
the professional practitioner market, and (ii) CBDMEDIC™, marketed
to the consumer market. Abacus' products are offered across the
United States and are produced by a contract manufacturer in a cGMP
compliant and audited manufacturing facility.
To learn more
about Abacus, visit
www.abacushp.com
For further
information: please contact
Hank Hague,
CFO, of
the Company, at 416-848-1457 or investorrelations@abacushp.com